Clinical and intestinal histopathological findings in SARS-CoV-2/COVID-19 patients with hematochezia

Clinical history and hospital course for case 1

A 67-year old man with a past medical history of obesity (108.9kg, Body Mass Index 38.45 kg/m²), diabetes mellitus type 2, hypertension, hyperlipidemia, and left bundle branch block presented to the emergency department with fever and chills for 8 days and cough with shortness of breath for 3 days. The patient received hydroxychloroquine and azithromycin from his primary care provider for presumed COVID-19 infection but discontinued by the patient after a few days. On admission, nasopharyngeal swab was positive for SARS-CoV-2 virus. COVID-19 pneumonia was complicated by acute hypoxic respiratory failure requiring intubation. His nasal swab was also positive for methicillin-susceptible staphylococcus aureus. The patient’s hospital course was further complicated by a non-ST-elevation myocardial infarction, atrial fibrillation with rapid ventricular rate, diabetes insipidus, toxic encephalopathy, acute kidney injury, and right upper and lower extremity weakness. He also developed acute occlusive deep vein thrombosis of his right peroneal vein for which he received apixaban. His medications included azithromycin, hydroxychloroquine, ceftriaxone, fluconazole, vancomycin, piperacillin/tazobactam, and cefazolin.

On day 33 of hospitalization, the patient passed frank red blood per rectum coupled with hemodynamic instability requiring blood transfusion. Colonoscopy was performed to identify the source of bleeding. At the time of gastrointestinal (GI) bleeding, he was on pantoprazole, albuterol, aspirin (low dose) fluconazole, furosemide, oxycodone, and piperacillin-tazobactam. Stool tests was negative for pathogens. Anticoagulation was stopped temporarily in the setting of active bleeding.

Colonoscopy findings

Notable findings included a few scattered non-bleeding erosions and shallow ulcerations in the transverse colon, hepatic flexure, and ascending colon (shown in Figure 1a). Biopsies of the ulcerated mucosa and of normal mucosa were obtained. The terminal ileum appeared normal. The source of hematochezia was considered to be from the small scattered proximal colonic erosions and shallow ulcers, exacerbated by patient’s use of apixaban.

• Download figure
• Open in new tab

Figure 1.

Colonoscopic findings (a, c) and histopathology of biopsies (b, d) counterstained with haematoxylin and eosin (x 100), (a) Case 1, transverse colon with erosion (yellow arrow), (b) Case 1, colonic mucosa with erosion, withered crypts, and nonspecific acute inflammation, consistent with ischemic pattern of injury, (c) Case 2, ileocecal valve with erosions (yellow arrow), (d) Ileocolic mucosa with edema, mildly active nonspecific inflammation and focally increased eosinophils in the lamina propria.

Histopathologic findings

The colonic mucosa featured an erosion, withered crypts, and nonspecific acute inflammation (shown in Figure 1b). The overall findings were consistent with an ischemic pattern of injury. Alternate possibilities of infection and drug/medication mediated mucosal injury were raised. No specific features of chronicity were identified. No viral cytopathic changes or microthrombi were seen. An immunohistochemical stain for cytomegalovirus was negative.

Outcome

On day 18, the patient had a tracheostomy placement and was decannulated on day 35. GI bleeding resolved spontaneously, and anticoagulation was resumed. On day 49 he was discharged home with rehabilitation.

Clinical history and hospital course for case 2

A 68-year old man with a past medical history of tobacco use, obesity (81.6 kg Body weight, 29 kg/m² BMI), diabetes mellitus 2, hypertension, hyperlipidemia, and coronary artery disease was brought to the emergency department for cough, fever, loose stools and altered mental status for five days. On admission, nasopharyngeal swab was positive for SARS-CoV-2 virus by PCR. COVID-19 pneumonia was complicated by acute hypoxic respiratory failure requiring intubation. His clinical course was complicated by sepsis, acute kidney injury requiring peritoneal dialysis, ileus, toxic metabolic encephalopathy, and candidemia (candida tropicalis and candida glabrata). On day 40 of his hospitalization, intermittent hematochezia requiring blood transfusion were noted. A subset of his critical laboratory parameters is highlighted in Table 2. CT abdomen pelvis showed the bowel was of normal caliber with no evidence of obstruction. Colonoscopy was performed to identify the source of bleeding. At the time of the bleeding, the patient was being treated with fluconazole, meropenem, micafungin, intravenous vancomycin, and ampicilin-sulbactum.

Colonoscopy findings

Patchy, deeply ulcerated mucosa with significant edema and decreased vascular pattern was present in the cecum with involvement of the ileocecal valve (shown in Figure 1c). There was diffuse oozing of the mucosa and the endoscopic appearance of the mucosa was clinically consistent with ischemic colitis. The ileocecal valve showed significant edema and ulceration. Biopsies were taken with cold forceps for histologic evaluation. Normal mucosa was found in the remaining portions of the colon.

Histopathological findings

The cecal mucosa showed focal edema, mildly active nonspecific inflammation and focal increased eosinophils in the lamina propria. There was no definitive evidence of ischemia (shown in Figure 1d).

Clinical outcome

Gastrointestinal bleeding resolved spontaneously. Patient was decannulated on day 54 and admitted to the rehabilitation unit.

Discussion/Conclusion

Gastrointestinal manifestations of COVID-19 are seen more often than originally suspected in COVID-19 patients [9-11].The cases presented are male patients above 65 years of age with complicated and prolonged hospitalizations. Although both patients presented with severe COVID-19 pneumonia resulting in hypoxic and respiratory failure on arrival, only one presented with gastrointestinal symptoms in the form of diarrhea. Both patients were obese and with cardiac comorbidities that are known to increase the morbidity and mortality in such cases [12]. The hospital courses for both patients were remarkable for lower GI bleeding in the latter part (>40 days) of hospitalization. Colonoscopies were remarkable for scattered erosions and ulceration clinically compatible with ischemia. The pathologic findings of the GI tract showed nonspecific acute inflammation and ischemic pattern of injury; however, drugs/medication, infections could not be completely ruled out. Both patients were on multiple medication, anticoagulants and antibiotics and antifungal agents at the time of hematochezia. Lower GI bleeding is an uncommon manifestation of COVID-19 and has been recently reported as a presenting symptom in an elderly male [13]. It is unclear if the GI symptoms of COVID-19 infection are caused by thrombosis due to altered coagulation profile (shown in Table 1 and 2) or as a consequence of tissue damage secondary to an immune response, rather than a direct interaction of these epithelial cells with the virus [14]. Additionally, an abnormal coagulation profile featuring significantly elevated D-dimer, fibrin degradation product levels, increased prothrombin time and activated partial thromboplastin time have also been reported in COVID-19 patients [15] and was also seen in our patients.

To our knowledge, this is the first histopathological and clinical correlation from colonic biopsies of two patients with severe COVID-19 pneumonia complicated by hematochezia during the later phase of their prolonged hospitalizations. Potential etiologies for the colonoscopic and histopathological findings include thromoembolic events specifically microthrobi which may be evident in resection and autopsy specimen rather than biopsy samples, or related to damage caused directly by the viral cytopathic effect or related to the cytokine storm, ischemia/hypotension injury or a drug-induced injury. Careful review of medications, management of coagulation profile and consultation with gastroenterology is warranted to improve morbidity and mortality outcomes.